Introduction {#S0001}
============

*Enterobacteriaceae* as a Gram-negative bacteria is the cause of various acquired infections including urinary tract, bloodstream, and lower respiratory tract infections.[@CIT0001] Carbapenems are often considered as a last resort of therapeutic option for infections due to *Enterobacteriaceae*.[@CIT0002] Carbapenem resistance refers to the ability of bacteria to survive and grow in the presence of clinically relevant concentrations of carbapenems.[@CIT0003] Emergence and dissemination of carbapenem resistance have been increasingly reported across the world which limits the usage of carbapenems.[@CIT0004] Carbapenem-resistant *Enterobacteriaceae* (CRE) is a significant clinical and public health concern.[@CIT0005] Considering their transmissibility and limited treatment options against CRE, the Centers for Disease Control and Prevention (CDC) considers CRE as specially dangerous.[@CIT0006] CRE is often resistant to all β-lactam drugs and simultaneously they often carry mechanisms conferring resistance to other antimicrobial classes. The infections with these bacteria are associated with increased mortality rates and higher healthcare costs.[@CIT0007],[@CIT0008] Currently, treatment options for CRE infections are limited to few antibiotics including polymyxin, tigecycline, fosfomycin, and aminoglycosides, or in combination with other antibiotics.[@CIT0009] To initiate/optimize antibiotic therapy and to control CRE infections, early detection of carbapenemase production and other mechanisms is necessary.[@CIT0010] There are three primary mechanisms by which *Enterobacteriaceae* employ resistance to carbapenems:[@CIT0003] (a) enzymatic hydrolysis of carbapenems by carbapenemases, enzymes that break down carbapenems (such as carbapenemase encoding genes, NDM, KPC, VIM, OXA, and IMP), (b) expression of efflux pumps, actively extruding carbapenems from the bacterial cell, and (c) reduction of outer membrane permeability via production of beta-lactamases (AmpC) in combination with alterations in the bacterial cell membrane (porin mutations in *OmpK35* and *OmpK36*).[@CIT0001],[@CIT0003],[@CIT0011] Recent breakpoints for CRE often detect all clinically important resistance mechanisms (especially carbapenemase genes).[@CIT0012]

Several Iranian studies during the last decade are clarified CRE, but most of these studies focus on carbapenemase genes detection.[@CIT0013]--[@CIT0015] According to the data on the prevalence of CRE, the molecular characteristics and carbapenem resistance mechanisms in CRE are poorly known in our region. The present study aimed to assess the prevalence rate of CRE and to monitor the antimicrobial susceptibility, and to perform phenotypic and genotypic evaluation of resistance mechanisms of CRE in Tabriz, Iran.

Materials and Methods {#S0002}
=====================

Bacterial Strains {#S0002-S2001}
-----------------

*Enterobacteriaceae* isolates were recovered from clinical samples of Tabriz hospitals, Iran. The isolates were identified using conventional biochemical tests in the Department of Microbiology, Tabriz University of Medical Sciences, Iran. The inclusion criteria were reduced susceptibility to at least one carbapenem (imipenem, meropenem, and ertapenem) according to the Clinical and Laboratory Standards Institute (CLSI) (2019, 29th) guideline. A total of 60 non-duplicate CRE isolates were collected during a 9-month period from October 2018 to June 2019.

Antimicrobial Susceptibility Testing {#S0002-S2002}
------------------------------------

We performed the susceptibility testing by the Kirby--Bauer method in Mueller--Hinton agar according to CLSI (2019, 29th) guideline. The antibiotic disks of imipenem (10 µg), meropenem (10 µg), ertapenem (10 µg), aztreonam (30 µg), cefixime (5 µg), ceftazidime (30 µg), cefotaxime (30 µg), cefepime (30 µg), cefazolin (30 µg), tobramycin (10 µg), amikacin (30 µg), gentamicin (10 µg), tetracycline (30 µg), and Piperacillin-tazobactam, Trimethoprim-sulfamethoxazole (1.25/23.75 μg) were tested for the antimicrobial susceptibility.[@CIT0016] The results of susceptibility testing were validated using the American Type Culture Collection (ATCC) quality control strain *P. aeruginosa* ATCC 27853 and *Escherichia coli* ATCC 25922. The minimum inhibitory concentrations (MICs) for the imipenem, meropenem, and colistin were determined using the micro-broth dilution method. The MICs were defined as the lowest concentration inhibiting an evident growth of the bacteria and interpreted according to the guidelines of the CLSI (2019, 29th).[@CIT0016]

Detection of AmpC Overproduction {#S0002-S2003}
--------------------------------

AmpC overproduction was confirmed according to the method described by Martínez et al. The isolates were considered as AmpC overproducer when there was at least a twofold dilution difference between the MICs of imipenem and those of imipenem plus cloxacillin.[@CIT0017]

Efflux Pump Inhibitor Tests {#S0002-S2004}
---------------------------

MICs of meropenem were determined alone and in the presence of phenylalanine arginine-naphthylamide dihydrochloride (PaβN) as an inhibitor of RND pumps of *Enterobacteriaceae*. A two-fold decline in MICs after addition of PAN was considered significant.[@CIT0018]

Detection of Carbapenemase Enzymes by the Phenotypic Tests {#S0002-S2005}
----------------------------------------------------------

All the carbapenem-resistant isolates were subjected to further evaluation by two methods. Modified Hodge Test (MHT) was performed according to the protocol recommended by CLSI instructions.[@CIT0019] The Carba NP test was performed as described previously.[@CIT0020] Brieﬂy, one inoculation loop (10 μL) of the isolate, recovered from MHA, was suspended in 200 μL of 0.02% cetyl trimethyl ammonium bromide (CTAB); then 100 μL of the bacterial suspension was added to 100 μL of diluted phenol red solution containing 0.1 mM ZnSO 4 (pH = 7.5) supplemented with 6 mg/mL of imipenem. The phenol red solution, with no antibiotic, was used as a control tube for each isolate. Both tubes were vortexed and incubated at 37°C for a maximum of two hours. The color of the test tube changed to full yellow or orange, indicating carbapenemase-producing isolate, while the control tube remained red.[@CIT0020]

PCR Amplification of Carbapenem Resistance Genes and Porin Coding Genes {#S0002-S2006}
-----------------------------------------------------------------------

All isolates that were phenotypically resistant to carbapenems were screened for the carbapenemase and porin encoding genes. The DNA was extracted by the CTAB method as described previously.[@CIT0021] PCR assays were performed using primers specific for the *bla*~KPC~, *bla*~VIM~, *bla*~IMP~, *bla*~NDM~, and *bla*~OXA-48-like~ carbapenemase encoding genes, as well as *OmpK35* and *OmpK36* as porin coding genes ([Table 1](#T0001){ref-type="table"}).[@CIT0022],[@CIT0023] PCR products underwent electrophoresis in 1.5% agarose gel, and after staining with 0.5 µg/mL safe stain, they were visualized under ultraviolet (UV) light. *P. aeruginosa* (*bla*~VIM~ and *bla*~IMP~,) and *Klebsiella pneumoniae* (*bla*~KPC~, *bla*~NDM~, and *bla*~OXA-48-like~) were used as controls in this study.Table 1List of Primers and Expected Amplicon Size in This StudyGeneForward Sequence \[5--3\]Reverse Sequence \[5--3\]Amplicon Size (bp)Reference*bla*~KPC~CGTCTAGTTCTGCTGTCTTGCTTGTCATCCTTGTTAGGCG798\[[@CIT0022]\]*bla*~NDM~GGTTTGGCGATCTGGTTTTCCGGAATGGCTCATCACGATC621\[[@CIT0022]\]*bla*~OXA-48-like~GCGTGGTTAAGGATGAACACCATCAAGTTCAACCCAACCG438\[[@CIT0022]\]*bla*~IMP~GGAATAGAGTGGCTTAAYTCTCGGTTTAAYAAAACAACCACC232\[[@CIT0022]\]*bla*~VIM~GATGGTGTTTGGTCGCATACGAATGCGCAGCACCAG390\[[@CIT0022]\]*OmpK35*CTCCAGCTCTAACCGTAGCGGGTCTGTACGTAGCCGATGG241\[[@CIT0023]\]*OmpK36*GAAATTTATAACAAAGACGGCGACGTTACGTCGTATACTACG305\[[@CIT0023]\]

Statistical Method {#S0002-S2007}
------------------

The results were analyzed using the descriptive statistics in SPSS software for Windows (version 23 SPSS Inc., Chicago, IL, USA). In this study, p≤ 0.05 was considered statistically significant.

Results {#S0003}
=======

Sixty isolates were resistant to at least one of the tested carbapenem (imipenem, meropenem, and ertapenem) antibiotics. Based on conventional microbiologic tests, 50 *K. pneumoniae* isolates, 6 *E. coli* isolates, and 4 *Enterobacter* spp. isolates were identified.

The resistance rates to imipenem, meropenem, and ertapenem were 96%, 96%, and 100%, respectively. Amikacin had the highest susceptibility rate (85%) followed by tobramycin (43%) ([Figure 1](#F0001){ref-type="fig"}). Amikacin was found to be the most effective drug against KPC-positive and VIM-positive isolates while other tested carbapenemase coding genes had variable susceptibilities to amikacin.Figure 1Antimicrobial susceptibility patterns of *K. pneumoniae, E. coli,* and *Enterobacter* spp. isolates.

The micro-broth dilution results indicated that all isolates were resistant to imipenem and meropenem (MIC ≥4 µg/mL). Further, 10 isolates were highly resistant (MIC ≥ 64 mg/mL) to imipenem and meropenem, respectively ([Figure 2](#F0002){ref-type="fig"}). The micro-broth dilution results showed that all isolates were susceptible to colistin with MIC≤0.5 mg/mL. MIC~50~ for imipenem and meropenem was 8 µg/mL and 16 µg/mL, while the MIC~90~ of agents was 32 µg/mL and 64 µg/mL, respectively. MIC~90~ and MIC~50~ values were defined as the lowest concentration of the antibiotic at which 90% and 50% of the isolates were inhibited, respectively. Note that the MIC~90~ of isolates observed to be within the non-susceptible range.Figure 2Distribution of imipenem and meropenem MICs in *K. pneumoniae, E. coli,* and *Enterobacter* spp. isolates.

Reduced MICs of meropenem and imipenem in AmpC overproduction isolates in CRE with/without inhibitor were found in 7 (11.6%) isolates. These isolates had carbapenem activity with a decline of MIC up to twofold by overproduction of AmpC. AmpC overproduction was observed in all of *Enterobacter* spp. and three *K. pneumoniae* isolates.

In this study, the isolates showed less than a threefold reduction in the MIC of meropenem in the presence of efflux pump inhibitor (PAbN) among 60 CRE isolates.

Carba NP ﻿test detected carbapenemase in 59 (98%) isolates, except one isolate (*Enterobacter* spp.) which was negative for carbapenemase genes. In addition, carbapenemase activity was detected by MHT in 57 (95%) isolates. Three carbapenemase producer isolates were not detected by MHT assay, where two isolates were *K. pneumoniae* (NDM-positive), and one isolate was *Enterobacter* spp. (overproduction of AmpC). The sensitivity and specificity of Carba NP test and MHT were 98% and 95%, and 100% and 100%, respectively.

Fifty-nine of 60 isolates (98.3%) were positive for carbapenemase genes. The most common carbapenemase genes were *bla*~OXA-48-like~ (72.8%) followed by *bla*~NDM~ (50.8%), *bla*~IMP~ (18.6%), *bla*~VIM~ (11.8%), and *bla*~KPC~ (6.7%) ([Table 2](#T0002){ref-type="table"}). Among the isolates, the percentage of carbapenemase genes in *K. pneumoniae* was *bla*~OXA-48-like~ (78%), *bla*~NDM~ (48%), *bla*~IMP~ (22%), *bla*~VIM~ (12%), *bla*~KPC~ (8%); in *E. coli* was *bla*~NDM~ (100%), *bla*~VIM~ (16.7%), and in *Enterobacter* spp. was *bla*~OXA-48-like~ (75%). In one isolate of *Enterobacter* spp., none of the tested carbapenemase genes was detected. Among the 59 isolates that were positive to at least one of the tested genes, 29 isolates had one carbapenemase gene, 25 isolates had two genes, and 5 isolates had three genes. The *bla*~IMP~ and *bla*~KPC~ were detected only in *K. pneumoniae* isolates ([Table 3](#T0003){ref-type="table"}). As reported in [Table 2](#T0002){ref-type="table"}, 12 distinct combination patterns were recognized among 59 carbapenemase genes PCR-positive isolates.Table 2The Susceptibility Testing Results in Carbapenemase-Producing IsolatesGenotypeSpecies N (%)AntibioticsMIC (µg/mL)48163264*bla*~OXA-48-like~*K. pneumoniae* 15 (25.4)\
*Enterobacter* spp. 3 (5.1)IMI\
MEM5\
27\
14\
102\
50\
0*bla*~NDM~*K. pneumoniae* 6 (10.1)\
*E. coli* 5 (8.8)IMI\
MEM2\
14\
34\
50\
11\
1*bla*~OXA-48-like~ + *bla*~NDM~*K. pneumoniae* 8 (13.5)IMI\
MEM3\
11\
32\
32\
10\
0*bla*~NDM~ + *bla*~VIM~*K. pneumoniae* (1.6)\
*E. coli* 1 (1.6)IMI\
MEM0\
01\
10\
00\
01\
1*bla*~NDM~ + *bla*~IMP~*K. pneumoniae* 3 (3.3)IMI\
MEM0\
12\
11\
00\
10\
0*bla*~OXA-48-like~ + *bla*~IMP~*K. pneumoniae* 6 (10.1)IMI\
MEM0\
04\
31\
11\
20\
0*bla*~OXA-48-like~*+ bla*~VIM~*K. pneumoniae* 4 (6.7)IMI\
MEM1\
01\
11\
11\
20\
0*bla*~OXA-48-like~*+ bla*~KPC~*K. pneumoniae* 1 (1.6)IMI\
MEM0\
00\
11\
00\
00\
0*bla*~NDM~*+ bla*~KPC~*K. pneumoniae* 1 (1.6)IMI\
MEM0\
00\
01\
10\
00\
0*bla*~OXA-48-like~*+ bla*~NDM~ + *bla*~IMP~*K. pneumoniae* 2 (3.3)IMI\
MEM0\
01\
10\
00\
01\
1*bla*~OXA-48-like~*+ bla*~NDM~ + *bla*~VIM~*K. pneumoniae* 1 (1.6)IMI\
MEM0\
00\
00\
00\
01\
1*bla*~OXA-48-like~*+ bla*~NDM~ + *bla*~KPC~*K. pneumoniae* 2 (3.3)IMI\
MEM0\
00\
00\
02\
00\
2[^1] Table 3The Frequency of Carbapenemase Genes and AmpC Overproduction in CRE IsolatesGenotypeK. pneumoniaeE. coliEnterobacter spp.*bla*~OXA-48-like~3903*bla*~NDM~2460*bla*~VIM~610*bla*~IMP~1100*bla*~KPC~400*AmpC*304

Of 50 isolates of *K. pneumoniae*, the genes coding for porin protein (*ompK35* and *ompK36*) were not detected in 10 and 7 *K. pneumoniae* isolates, respectively. Genes coding for the porins (*ompK35* and *ompK36*) were detected in all *K. pneumoniae* recovered from body fluid specimens in blood, wound, and urine samples.

Discussion {#S0004}
==========

Resistance to carbapenems as the last-resort antibiotics for the treatment of infections caused by the CRE is a major health concern. The increase in CRE is a serious matter due to high case-fatality rates (\>30%).[@CIT0024]--[@CIT0026] Studying the mechanisms of CRE is an essential step in planning a national public health strategy for this emerging pathogen.[@CIT0027] Several studies have been studied the mechanisms of resistance to carbapenem in CRE isolates from Iran. However, most of these studies focus on the carbapenemase associated mechanisms.[@CIT0015],[@CIT0028] In the present study, carbapenemase-associated mechanisms and also other mechanisms of CRE such as efflux pump, AmpC overproduction, and porin related mechanism were studied. Because of the impact geographical characteristics on susceptibility pattern CRE, the results of such a study can be applied in the treatment of CRE isolates from Tabriz, Iran.

In this research, *K. pneumoniae* was the most common CRE which was isolated from 50 specimens followed by *E. coli* and *Enterobacter* spp. This agrees with the previous studies reporting that *K. pneumoniae* and *E. coli* were predominant CRE among *Enterobacteriaceae*.[@CIT0004],[@CIT0029]-[@CIT0031] We found a high rate of antimicrobial resistance. In addition, these CRE pose the greatest risk to the public health because of their high prevalence, high potential for causing a wide range of clinical infections, co-resistance to Beta-lactam as well as other antimicrobial agents (such as aminoglycosides and fluoroquinolones).[@CIT0004],[@CIT0029]

Understanding the antibiotic susceptibility patterns of CRE is important for antibiotic therapy of infections. In our study, amikacin showed the highest susceptibility rate (85%). Similar reports previously described by Gao et al,[@CIT0031] Park et al,[@CIT0032] Freire et al,[@CIT0033] and Chen et al[@CIT0034] showed that amikacin had high in vitro activity against CRE isolates. In contrast, some of the studies reported high rates of resistance to aminoglycosides chiefly amikacin.[@CIT0029],[@CIT0035] These findings could be attributed to the differences in the characteristics of the various carbapenemase types, geographical area, and usage of antibiotics.[@CIT0030] Overall, this result and previous reports suggested that some active agents such as amikacin might be appropriate options for the treatment of CRE.[@CIT0034] Our study revealed that all isolates had MIC ≥4 µg/mL and resistance to imipenem plus meropenem. The MIC~50~ and MIC~90~ of carbapenems were 8--16 µg/mL and 32--64 µg/mL, respectively. Other studies confirmed that the most frequent non-susceptible carbapenems were meropenem and imipenem.[@CIT0004],[@CIT0031] Therefore, the CLSI and EUCAST recommend the MIC test for routine clinical isolates.[@CIT0016],[@CIT0036]

The carbapenem-hydrolyzing activity of class C-beta lactamases has been reported.[@CIT0018] In this study, the overproduction of AmpC was confirmed in all isolates of *Enterobacter* spp. and 6% *K. pneumoniae* isolates. Several studies have reported that AmpC producer in *K. pneumoniae* ranged from 7.8% to 43%.[@CIT0037]--[@CIT0039] Similar to a previous study, resistance to carbapenem among *Enterobacter* spp. was high.[@CIT0040] Class C-beta lactamase enzymes appeared as an important contribution to carbapenem resistance among *Enterobacter* spp. in our region.

Antibiotic efflux pumps are not considered as an important mechanism of antimicrobial resistance in CRE.[@CIT0041] Similar to other studies carried by Kim et al,[@CIT0042] Dupont et al,[@CIT0018] and Osei Sekyere et al,[@CIT0043] in the present study, we did not find any efflux pump activity by the phenotypic method. Previous studies found the efflux pump by the molecular technique such as PCR and observed that AcrAB efflux pump and mdtK efflux pump existed in CRE isolates.[@CIT0023],[@CIT0041]

In the current study, carbapenemase enzymes were detected by Carba NP test and MHT in 98% and 95%, respectively, which was in line with another study carried by Elawady et al[@CIT0044] and Garg et al[@CIT0045] who reported good sensitivity and specificity of Carba NP test.

The presence of carbapenemase genes was found in 42 isolates for *bla*~OXA-48-like~. Also, 30 isolates were positive for *bla*~NDM~, 11 isolates were positive for *bla*~IMP~, 7 isolates were positive for *bla*~VIM~, and 4 isolates were for *bla*~KPC~. *bla*~OXA-48-like~ was the most common gens in *K. pneumoniae*, while *bla*~NDM~ was the most common in *E. coli*. These findings are also congruent with other results obtained by the previous studies.[@CIT0046],[@CIT0047] In our study, *bla*~VIM~ and *bla*~KPC~ were the least frequent, which is in agreement with other results reported by Shibl et al[@CIT0048] and Cakirlar et al.[@CIT0049] This similarity can be due to the population size studied, the proximity of geographic regions, and the similarity of antibiotic usage.

Porins such as *OmpK35* and *OmpK36* have a critical role in the penetration of antibiotics into cells and susceptibility to cephalosporins and carbapenems. It has also been reported that loss of *OmpK35* and *OmpK36* plays a key role in *K. pneumoniae* virulence and infection.[@CIT0023] Deletion of *OmpK36* and *OmpK35* can lead to a reduction in virulence and infection. In the current study, *K. pneumoniae* isolates harbored high distribution of *OmpK35* and *OmpK36* genes coding for porin protein which was in accordance with studies carried by Wasfi et al[@CIT0023] and Ranjbar et al[@CIT0041] who reported a high prevalence of these genes.[@CIT0023] The authors suggest the detection of porin coding genes and efflux pump inhibitors by Real-time PCR. Furthermore, doing molecular typing methods could help to identify the origin of resistant strains and designing the program to control their spread. The resistance rate to carbapenems is high. We found that amikacin is an effective antibiotic for the treatment of CRE isolates. The increasing resistance to amikacin in CRE isolates is an alarming signal for monotherapy with amikacin. This study revealed that carbapenemase production and overproduction of AmpC are the main resistance mechanisms to carbapenem among CRE isolates in the West Azerbaijan, Iran. The most common carbapenemase gene was *bla*~OXA-48-like.~ Based on the results, early detection of carbapenemase-producing isolates with rapid and reliable tests such as Carba NP test may be useful for the treatment of infections induced by CRE isolates.
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[^1]: **Abbreviations:** MIC, minimum inhibitory concentration; IMI, imipenem; MEM, meropenem.
